Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of EGFR Status Based Gefitinib Neoadjuvant Therapy in NSCLC Patients

NCT00986284 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.

NCT NCT00986284
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00986284 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of EGFR Status Based Gefitinib Neoadjuvant Therapy in NSCLC Patients
Lead sponsor
Tianjin Medical University Cancer Institute and Hospital
Phase
Phase 2
Overall status
Suspended
Start date
September 30, 2009
Completion date
November 30, 2016
Enrollment
102 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer